This biotechnology company develops antibody-drug conjugates (ADCs) and antibody fragment-drug conjugates (FDCs) for oncology treatments. Their proprietary enzymatic conjugation platform aims to improve the efficacy and targeting of therapies for solid tumors, potentially enhancing drug delivery and reducing side effects.
Funding
Funding not disclosed
Founders
Product
Problem
Traditional antibody-drug conjugates (ADCs) often face challenges in effectively penetrating solid tumors, leading to suboptimal drug delivery and potential toxicity due to off-target effects. The large size of conventional ADCs limits their ability to diffuse into dense tumor tissues, hindering their therapeutic efficacy, particularly in cancers like pancreatic cancer.
Solution
AbTx is a preclinical-stage biotechnology company that is developing next-generation oncology treatments based on its proprietary Therano-Stick™ platform. This platform enables innovative enzymatic conjugation of antibody fragments, generating Fragment Drug Conjugates (FDCs) with improved tumor penetration and reduced toxicity. By using microbial transglutaminase to conjugate payloads to specifically engineered glutamine tags on antibody fragments, AbTx creates FDCs with site-specific conjugation, preserved antibody activity, and reduced heterogeneity. These FDCs are smaller than full-length antibodies, allowing for better drug delivery to target sites within solid tumors, while also optimizing drug exposure and clearance.
Target Audience
The primary target audience includes researchers and pharmaceutical companies focused on developing targeted therapies for solid tumors, particularly those seeking to improve drug delivery and reduce off-target effects in challenging cancers like pancreatic cancer.
Features
- Therano-Stick™ platform for site-specific enzymatic conjugation of antibody fragments
- Generation of FDCs (Fab, scFv, VHH) with tailored pharmacokinetic properties
- Q-Tag technology for precise payload location and preservation of antibody activity
- Reduced heterogeneity compared to chemical conjugation methods
- Improved stability through transglutaminase cross-linking under mild conditions
- Versatile mAb design applicable to various antibody formats and payloads (drugs, radioelements, dyes)
- Enhanced penetration into solid tumors due to smaller FDC size
- Lower immunogenicity risk compared to certain chemical conjugation approaches
- More eco-friendly process using biocompatible reagents and conditions